Gilead Sciences (GILD) : On Friday, The money flowed into the Gilead Sciences (GILD) stock with an uptick to downtick ratio was recorded at 1.41. Transactions worth $152.92 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $108.72 million. The total money flow into the stock was $44.2 million. The block trades reveal a bullish bias with an up-down ratio of 54.39. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $41.82 million of block transactions on upticks. The value of block trades on downticks was $0.77 million, indicating lower selling interest. The total money flow in block trades was $41.05 million. In terms of price action, Gilead Sciences (GILD) traded down $0.53 during the session at $76.89. Compared to the previous days closing, the stock was down only by -0.68%. For the week, the stock is -3.61%, over previous weeks closing.
The company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. Institutional Investors own 78.19% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -6.2%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Gilead Sciences Inc, Lofton Kevin E had sold 3,500 shares worth of $286,895 in a transaction dated August 24, 2016. In this transaction, 3,500 shares were sold at $81.97 per share.
Gilead Sciences (NASDAQ:GILD): stock was range-bound between the intraday low of $76.67 and the intraday high of $77.76 after having opened at $77.62 on Fridays session. The stock finally closed in the red at $77.62, a loss of -0.68%. The stock remained in the red for the whole trading day. The total traded volume was 7,956,223 shares. The stock failed to cross $77.76 in Fridays trading. The stocks closing price on Thursday was $77.42.
Gilead Sciences (GILD) : During the past 4 weeks, traders have been relatively bearish on Gilead Sciences (GILD), hence the stock is down -4.25% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.09% relative to the S&P 500. The 4-week change in the price of the stock is -4.38% and the stock has fallen -3.61% in the past 1 week.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.